Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Clear all
Completed Phase 2 Interventional Results available

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

NCT01903031
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Nuvaring, EFV, ATV/r, TDF, NRTIs
Device · Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 23, 2026, 6:28 AM EDT
Recruiting Phase 2 Interventional

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

NCT04375800
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Doravirine, 2 NRTIs, DOR/3TC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
4 Weeks to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

NCT01440569
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
COBI, DRV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines

NCT01172535
View directory record Official record
Conditions
HIV
Interventions
Lopinavir/ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Weeks and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

NCT03739996
View directory record Official record
Conditions
HIV Infections
Interventions
Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, Standard of Care (SOC) ART
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Results available

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

NCT02858401
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vesatolimod, Placebo, ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

NCT00799864
View directory record Official record
Conditions
HIV-1
Interventions
Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
6 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Syracuse, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

NCT03332095
View directory record Official record
Conditions
HIV Infections
Interventions
Doravirine (DOR), Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF), Antiretroviral (ARV) medications
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

NCT00002364
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

NCT00896051
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg, Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs), Etravirine (ETR) 200 mg, Tenofovir disoproxil fumarate (TDF) 300 mg
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
10
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Results available

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 23, 2026, 6:28 AM EDT
Terminated Phase 3 Interventional Results available

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

NCT00440271
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

NCT02422797
View directory record Official record
Conditions
HIV Infections
Interventions
DTG 50 mg, RPV 25 mg, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 23, 2026, 6:28 AM EDT
Terminated Phase 3 Interventional

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

NCT00028067
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Nelfinavir mesylate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
47
States / cities
Little Rock, Arkansas • Berkeley, California • Fountain Valley, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 4 Interventional

Switching Undetectables to Selzentry

NCT01866267
View directory record Official record
Conditions
Human Immunodeficiency Virus, AIDS
Interventions
Maraviroc
Drug
Lead sponsor
St. Hope Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen

NCT00051844
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Capravirine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
30
States / cities
Beverly Hills, California • Long Beach, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 3 Interventional

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

NCT00002378
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
97
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 6:28 AM EDT
Completed No phase listed Observational Results available

Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

NCT00119405
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

NCT04223778
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, ART
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Ft. Pierce, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 4 Interventional Results available

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

NCT01691794
View directory record Official record
Conditions
HIV, Pediatric
Interventions
Atazanavir, Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Phoenix, Arizona • Atlanta, Georgia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 23, 2026, 6:28 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

NCT00488059
View directory record Official record
Conditions
HIV Infections
Interventions
enfuvirtide [Fuzeon], Optimized background ARV, Integrase inhibitor
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Hobson City, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

NCT00262522
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Beverly Hills, California • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2012 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

NCT00870363
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

NCT00110305
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Sep 23, 2026, 6:28 AM EDT